Krystal Biotech, Inc. — Director's Dealing 2017

Sep 20, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2017-09-19

Reporting Person: ROSSI DINO A (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Series A Convertible Preferred Stock	123691	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$39.57	2027-06-01	Common Stock (18949)		Direct

Footnotes

F1: The Series A convertible preferred stock will automatically convert on a one-to-one basis into 123,691 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.

F2: The options were awarded on June 1, 2017 and vest ratably over a four-year period.